[Form 4] Nvidia Corp Insider Trading Activity

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) filed a Form 8-K dated 24 June 2025.

Item 1.01 – Material Agreement: The company executed Amendment No. 1 to its existing license agreement with Yuhan Corporation, effective 11 June 2025 and formally signed on 24 June. The amendment is connected to a 17 June 2025 term sheet with Intact Therapeutics, suggesting a coordinated expansion of collaborative development efforts. Specific financial terms, milestone obligations or royalty adjustments were not disclosed.

Item 5.07 – Submission of Matters to a Vote of Security Holders: The 30 June 2025 Annual Shareholder Meeting in Hanover, MD lacked a quorum and was adjourned without conducting business. The meeting will reconvene on 30 July 2025 at 1:00 p.m. EDT. The record date remains 1 May 2025; previously submitted proxies stay valid and proposals are unchanged.

Exhibits: 10.1 – Amendment No. 1 to the Yuhan License Agreement; 104 – Cover Page Inline XBRL data.

The filing signals ongoing partnering activity that could enhance the company’s pipeline while underscoring a temporary governance setback due to insufficient shareholder participation.

Positive

• Execution of Amendment No. 1 to the Yuhan license agreement reinforces a key strategic partnership and suggests progress in Processa’s development programs.
• Entry into a term sheet with Intact Therapeutics indicates additional collaborative opportunities that could expand the company’s pipeline or market reach.

Negative

• Annual shareholder meeting adjourned for lack of quorum, delaying formal corporate actions and highlighting potential shareholder disengagement.
• No financial details disclosed for the amended Yuhan agreement, limiting investor ability to assess economic impact.

Insights

Biopharma Financial Analyst

TL;DR – Yuhan amendment positive for pipeline; quorum miss neutral-negative; net impact modest.

The Yuhan license amendment, tied to a new term sheet with Intact Therapeutics, indicates Processa remains active in forging alliances that can de-risk development and potentially broaden geographic rights. Without disclosed economics, the amendment’s financial accretion cannot yet be quantified, but continuation of the partnership removes uncertainty around the relationship. Conversely, the inability to assemble a quorum delays routine corporate actions—often a symptom of retail-heavy or disengaged shareholder bases—but is unlikely to impede day-to-day operations. Overall, the 8-K is informational rather than catalytic, with a balanced risk-reward profile for investors.

Corporate Governance Expert

TL;DR – Governance hiccup from quorum failure; no immediate red flag.

Adjournment of the annual meeting highlights low voter turnout, which can reflect limited institutional ownership or communication gaps. Management mitigated risk by promptly rescheduling and keeping the record date intact, preserving voting integrity. Because proposals remain unchanged and proxies already cast stay valid, the administrative burden is minimal. Investors should still monitor whether the July reconvening reaches quorum; repeated failure could impede director elections or other essential resolutions. On balance, this is a minor governance issue rather than a material weakness.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JONES HARVEY C

(Last) (First) (Middle)

C/O NVIDIA CORPORATION

2788 SAN TOMAS EXPRESSWAY

(Street)

SANTA CLARA CA 95051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NVIDIA CORP [ NVDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		A		1,799	A	$0(1)	70,407	D
Common Stock								7,433,280	I	H.C. Jones Living Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 19, 2025 and 50% of the shares on May 20, 2026. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested.

2. Shares are held by H.C. Jones Living Trust, of which the Reporting Person is the trustee.

Remarks:

	/s/ Rebecca Peters, Attorney-in-Fact for Harvey C. Jones	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Processa Pharmaceuticals (PCSA) announce in its latest 8-K?

The filing reports an amended license agreement with Yuhan Corporation and the adjournment of the 2025 annual shareholder meeting due to lack of quorum.

When will PCSA reconvene its 2025 annual shareholder meeting?

The meeting is scheduled to reconvene on 30 July 2025 at 1:00 p.m. EDT in Hanover, MD.

Does the Yuhan amendment include new financial terms for PCSA?

The 8-K does not disclose any specific financial terms, milestone payments, or royalties associated with the amendment.

Will previously submitted PCSA proxies remain valid for the reconvened meeting?

Yes. Proxies already submitted remain valid, and shareholders who do not wish to change their vote need take no further action.

What exhibits were filed with the 8-K?

Exhibit 10.1—Amendment No. 1 to the Yuhan license agreement; Exhibit 104—Cover Page Inline XBRL data file.